Regeneron Pharmaceuticals Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals Inc. (REGN): $1,053.14

8.75 (+0.84%)

POWR Rating

Component Grades

Momentum

D

Stability

B

Sentiment

Quality

B

Add REGN to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#18 of 347

in industry

REGN Price/Volume Stats

Current price $1,053.14 52-week high $1,059.80
Prev. close $1,044.39 52-week low $684.80
Day low $1,041.25 Volume 1,291,700
Day high $1,059.80 Avg. volume 476,610
50-day MA $963.86 Dividend yield N/A
200-day MA $902.86 Market Cap 116.04B

REGN Stock Price Chart Interactive Chart >


Regeneron Pharmaceuticals Inc. (REGN) Company Bio


Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester CountyNew York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. (Wikipedia:Source)


REGN Latest News Stream


Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream


Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Regeneron Gains After Eye-Drug Patent Victory Over Viatris

(Bloomberg) -- Regeneron Pharmaceuticals Inc. rose the most in almost two months after a court ruled that the drugmaker’s patent rights were infringed by a cheaper copy of its eye drug developed by Viatris Inc. Most Read from BloombergThe Late-Night Email to Tim Cook That Set the Apple Watch Saga in MotionChinese Carmaker Overtakes Tesla as World’s Most Popular EV MakerBridgewater CEO’s Past Office Romance Led to Favoritism ClaimsXiaomi Unveils Its First EV, With Ambition to Be China’s Porsche o

Yahoo | December 27, 2023

7 Undervalued Nasdaq-100 Stocks for Bargain Hunters

Understandably, with the innovation sector printing a remarkable performance, all eyes have centered on Nasdaq-100 stocks.

Josh Enomoto on InvestorPlace | December 22, 2023

Where Will Regeneron Pharmaceuticals Be in 1 Year?

Can the stock continue its market-beating ways?

Yahoo | December 22, 2023

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | December 22, 2023

The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK

Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK are included in this Analyst Blog.

Yahoo | December 19, 2023

Read More 'REGN' Stories Here

REGN Price Returns

1-mo 6.92%
3-mo 9.30%
6-mo 20.45%
1-year 35.06%
3-year 91.29%
5-year 245.20%
YTD 19.91%
2023 21.73%
2022 14.25%
2021 30.72%
2020 28.66%
2019 0.53%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!